Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846495 · ClinicalTrials.gov registry record · Phase 4
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
A Phase 4 study, sponsored by Clinvest.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT00846495 is a Phase 4 study that has completed, run by Clinvest. The registered enrollment target is 55 participants.
The verdict
NCT00846495, a Phase 4 study, has completed, sponsored by Clinvest.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin) at Visit 2, subjects will treat daily with topiramate or during Prodrome with frovatriptan. Subjects complete a 2-month Treatment Period before exit at Visit 3.This study will compare the effectiveness of daily treatment vs. treatment during the pre-headache phase for prevention of migraine.
Interventions
- DRUG topiramate
- DRUG frovatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846495
The ClinicalTrials.gov registry entry for NCT00846495 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clinvest, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topiramate is the first listed.
NCT00846495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846495 about?
NCT00846495 is a clinical study titled "Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine". Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin)...
What is the current status of trial NCT00846495?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2009-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00846495?
The interventions under investigation include: topiramate (DRUG), frovatriptan (DRUG).
Who is sponsoring clinical trial NCT00846495?
This trial is sponsored by Clinvest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.